Plavix, which has brought Bristol-Myers Squibb (BMY) $42.8B over 15 years, loses its patent protection today. In total, 19 drugs are set to relinquish such protection in 2012 - dubbed the year of "pharmageddon" - costing the industry $38.5B. BMY is now pinning its hopes on the yet-to-be-approved blood thinner Eliquis to make up for Plavix.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Thu, 8:35AM)
at Benzinga.com (Wed, 12:57PM)
at CNBC.com (Feb 17, 2015)
at Investor's Business Daily (Jan 27, 2015)
at CNBC.com (Jan 20, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs